Ran Geng
About Ran Geng
Ran Geng is a Director at OrbiMed, with a background in biotechnology and healthcare investment. He has held various roles in prominent companies and has an educational background from institutions like The Wharton School and Stanford University.
Current Role at OrbiMed Advisors
Ran Geng currently serves as a Director at OrbiMed Advisors, a position he has held since 2023. In this role, he focuses on assisting companies in the biotech sector to reduce development costs. His expertise in the field enables him to provide valuable insights and strategic guidance to organizations looking to optimize their operations.
Previous Experience at OrbiMed
Prior to his current role, Ran Geng worked at OrbiMed in various capacities. He served as Vice President for 11 months from 2022 to 2023 and as Senior Associate for 11 months from 2021 to 2022. His tenure at OrbiMed has contributed to his understanding of the investment landscape in the life sciences sector.
Educational Background
Ran Geng has a robust educational background. He studied at The Wharton School, where he earned a Bachelor of Science in Engineering (BSE) with a focus on Operations and Management. He also attended the University of Pennsylvania, achieving a Bachelor of Arts in Computational Biology with a Pre-Medicine track. Additionally, he holds a Master of Science in Biomedical Informatics from Stanford University School of Medicine and was admitted to the 8-Year M.D. Program at Peking University.
Career in the Biotech and Investment Sector
Ran Geng has extensive experience in the biotech and investment sectors. He worked at Allergan in R&D for 11 months in 2012 and held various roles at Matrix Partners, including Associate, Senior Analyst, and Senior Associate, culminating in a promotion to Vice President in 2020. He also served as an Angel Investor at Life Science Angels from 2017 to 2019, where he focused on investing in technologies aimed at addressing healthcare resource inequality.
Involvement with Biotech Companies
Ran Geng has been involved with several biotech companies, including ArriVent Biopharma, Sirius Therapeutics, QuantX Biosciences, and Epigenic Therapeutics. His work with these organizations reflects his commitment to advancing healthcare solutions and addressing inefficiencies in healthcare delivery.